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Anti-ﬁbrotic therapyThe ﬁbrotic diseases encompass a wide spectrum of entities including such multisystemic diseases as systemic
sclerosis, nephrogenic systemic ﬁbrosis and sclerodermatous graft versus host disease, as well as organ-speciﬁc
disorders such as pulmonary, liver, and kidney ﬁbrosis. Collectively, given the wide variety of affected organs,
the chronic nature of the ﬁbrotic processes, and the large number of individuals suffering their devastating effects,
these diseases pose one of themost serious health problems in currentmedicine and a serious economic burden to
society. Despite these considerations there is currently no accepted effective treatment. However, remarkable
progress has been achieved in the elucidation of their pathogenesis including the identiﬁcation of the critical
role of myoﬁbroblasts and the determination ofmolecularmechanisms that result in the transcriptional activation
of the genes responsible for the ﬁbrotic process. Here we review the origin of the myoﬁbroblast and discuss the
crucial regulatory pathways involving multiple growth factors and cytokines that participate in the pathogenesis
of the ﬁbrotic process. Potentially effective therapeutic strategies based upon this new information are considered
in detail and themajor challenges that remain and their possible solutions are presented. It is expected that trans-
lational efforts devoted to convert this new knowledge into novel and effective anti-ﬁbrotic drugs will be forth-
coming in the near future. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to
human disease.
© 2012 Elsevier B.V. All rights reserved.1. The Problem
Fibrotic diseases encompass a wide spectrum of entities including
suchmultisystemic diseases as systemic sclerosis (SSc), sclerodermatous
graft versus host disease, and nephrogenic systemic ﬁbrosis, as well as
organ-speciﬁc disorders such as pulmonary, liver, and kidney ﬁbrosis
[1–8]. Although their etiology and causative mechanisms vary widely,
these conditions share the common feature of elevated expression of
genes encoding matrix proteins, and the resulting ﬁbrosis disrupts the
normal architecture of the affected organs, ultimately leading to their
dysfunction and failure [9–11]. Indeed, it is the persistent production of
extracellular matrix (ECM) macromolecules by activated mesenchymal
cells, known as myoﬁbroblasts, that distinguishes controlled repair oc-
curring during normal wound healing from the uncontrolled ﬁbrosis
that is the hallmark of ﬁbrotic diseases.
Collectively, given the wide variety of affected organs, the chronic
nature of the ﬁbrotic processes, and the large number of individualss: Translation of basic research
lar Medicine, Thomas Jefferson
ia, PA 19107, USA. Tel.: +1 215
enbloom).
l rights reserved.suffering their devastating effects, these diseases pose one of the
most serious health problems in current medicine and represent an
enormous challenge to health services, and a serious economic burden
to society. It has been estimated that as much as 45% of the mortality
in the Western developed countries is now caused by ﬁbrotic diseases
[11] and the mortality in underdeveloped or developing countries
caused by these diseases is likely to be even much higher. Despite
these considerations there is currently no accepted effective treatment.
However, recent identiﬁcation of the critical role of the myoﬁbroblast
and elucidation of crucial regulatory pathways resulting in the transcrip-
tional activation of the genes encoding collagens and other proteins re-
sponsible for the ﬁbrotic process has been of substantial importance
and has provided a sound basis for the development of novel and effec-
tive means of therapy. Unfortunately, the current lack of approved
drugs for treatment of these diseases indicates that recent knowledge
has not yet been translated into effective therapies, however, it can be
expected that this situation will be reversed in the near future.
2. Origin and critical role of activated ﬁbroblasts/myoﬁbroblasts
in ﬁbrotic tissues
Although the causative agents or initiating events of the ﬁbrotic
disorders are quite diverse, and their pathogenesis is variable, a com-
mon feature in affected tissues is the presence of large numbers of
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logical functions, including increased production of ﬁbrillar type I and
type III collagens, expression ofα-smoothmuscle actin (α-SMA), a mo-
lecularmarker of activatedmyoﬁbroblasts, and reduction in the expres-
sion of genes encoding ECM-degradative enzymes [12–15]. Regardless
of the etiological event, the accumulation of myoﬁbroblasts in affected
tissues and the uncontrolled persistence of their elevated biosynthetic
functions are crucial determinants of the extent and rate of progression
of the ﬁbrotic diseases, and of their clinical course, response to therapy,
prognosis, and mortality [9].
The origins of myoﬁbroblasts are diverse and may differ depending
on the affected organ and the initiating event. There are four important
sources of themyoﬁbroblasts encountered in theﬁbrotic tissues as illus-
trated in Fig. 1: i) Proliferation and activation of tissue resident ﬁbro-
blasts or perivascular and vascular adventitial ﬁbroblasts in response
to speciﬁc signals from inﬁltrating inﬂammatory cells resulting in
activation of quiescent ﬁbroblasts to a myoﬁbroblast phenotype
[16]. ii) Recruitment of ﬁbroblast precursor cells from bone marrow
through local release of activated chemokines. These circulating bone
marrow precursor cells are known as ﬁbrocytes, a unique cell population
expressing bone marrow cellular surface markers, such as CD34 protein,
but capable of ECM production. These cells can migrate from the blood-
stream in response to speciﬁc chemokine gradients and localize in tissues
undergoing pathological ﬁbrogenesis [17,18]. iii) Transdifferentiation of
epithelial cells tomyoﬁbroblasts, a process known as epithelial tomesen-
chymal transition (EMT), which is induced by transforming growth
factor β (TGF-β) and perhaps other polypeptides such as endothelin-1
(ET-1) or insulin growth factor [19–21]. In EMT, epithelial cells lose
their epithelial characteristics, including E-cadherin expression and
apical-basal polarity, and reorganize their cytoskeleton to acquire a
motile behavior and the phenotype of myoﬁbroblasts including the
expression of α-SMA and ﬁbroblast-speciﬁc proteins such as type I
collagen. Although some recent studies employing genetic cell line-
age tracing studies have raised controversy [22], numerous publica-
tions have described the occurrence of EMT in the course of renal,
pulmonary, and liver ﬁbrosis [21,23–25]. iv) Another type of cellular
transition similar to EMT, but in which endothelial cells undergo a
mesenchymal transition (EndoMT) has emerged as a possible mecha-
nism in pathological ﬁbrosis [26,27]. During EndoMT endothelial cells
lose their speciﬁc endothelial cell markers, such as vascular endothelial
cadherin (VE cadherin), and acquire a mesenchymal or myoﬁbroblastic
phenotype initiating expression ofα-SMA, vimentin, and type I collagen.
In addition, these cells also become motile and are capable of migrating
into surrounding tissues. Similar to EMT, EndoMT can be induced by
TGF-β [26,27].
Whereas investigations into the pathogenesis of ﬁbrotic diseases
have been ongoing for many decades, discoveries within the last ten
years have more fully characterized the molecular complexity of the
processes involved. Since its ﬁrst identiﬁcation in 1983 by Sporn and
collaborators [28–30] it has been known that transforming growth
factor-ß (TGF-β) a pleiotropic growth factor involved in the pathogen-
esis of numerous human diseases, plays a key role in ﬁbrotic diseases
by stimulating the production of various collagens and other ECM com-
ponents by activatedmesenchymal cells [29,31–33]. TGF-β also inhibits
the synthesis of matrix degrading metalloproteinases and stimulates
the production of tissue inhibitors of metalloproteinases [34]. However,
multiple recent ﬁndings have clearly identiﬁed numerous other cyto-
kines including interleukins 4, 6, and 13 and several novel signaling
pathways such as the Wnt, Hedgehog and Notch as potential partici-
pants. Several other important new insights have been made which
have a critical bearing on therapeutic approaches for the ﬁbrotic dis-
eases. There is a growing realization that the clinical manifestations
and the molecular pathogenesis of a given ﬁbrotic disease are highly
heterogeneous. As discussed above, besides the variety of causes, often
poorly understood, which may be responsible for initiating the ﬁbrotic
response there is also increasing complexity at the cellular andmolecularlevels. Despite this heterogeneity, however, the ﬁnal common result is
the excessive production of ECM. Thus, the focus of this review will be
on the cellular alterations and molecular pathways that play critical
roles in the ﬁbrotic response and to discuss potential strategies that
may allow identiﬁcation of potential therapeutic targets.
3. Critical molecular pathways participating in the ﬁbrotic response
3.1. Transforming growth factor beta (TGF-β)
The TGF-βs comprise three structurally similar proteins, TGF-β1,
TGF-β2 and TGF-β3, with a wide and diverse spectrum of biological
activities ranging from a role in embryonic development to regulation
of the immune response and to the development of exaggerated ﬁbrotic
responses [35,36].Whereas deregulated TGF-β signaling occurs in essen-
tially all ﬁbrotic reactions, the speciﬁc mechanisms vary depending on
the causative agent(s) and on the affected organ. TGF-β, initially pro-
duced as an inactive homodimeric peptide by numerous cell types, in-
cluding ﬁbroblasts and macrophages, is secreted into the ECM as a large
latent complex (Fig. 2). The latent TGF-β complex consists of latent
TGF-β binding protein covalently bound to a small latency complex
formed by a homodimer of TGF-βwhich is bound to an RGD-containing
N-terminal latency associated binding peptide [37,38]. TGF-β can under-
go several alternative proteolytic or conformational activating events
[39,40]. Once activated TGF-β binds to a constitutively active serine/
threonine transmembrane receptor kinase known as TGF-β receptor ll
(TβRII). The intracellular transduction pathways following TGF-ß bind-
ing to its cognate receptors are quite complex and involve either the
Smad pathways or non-Smad signaling pathways. The Smad pathways
are often referred to as the canonical pathway whereas the non-Smad
pathways are referred to as the non-canonical pathways.
3.2. Canonical TGF-ß signaling pathways
In the classic or canonical pathway the ligand-bound TβRII recruits
and phosphorylates a TGF-β receptor l (TβRI). The TβRl comprises a fam-
ily of proteins also known as ALK proteins, two of which, ALK-1 and
ALK-5, are involved in TGF-β signaling [41–43]. ALK-5 is the most com-
monTβRI and is phosphorylated by TβRII on three toﬁve serine and thre-
onine residues in a short 30 amino acid regulatory sequence. Signaling
from the TβRI to the nucleus then occurs through the receptor activated
RSmads, Smad2 or Smad3which are phosphorylated by TβRl. The phos-
phorylated Smad2/Smad3 then bind to the co-Smad, Smad4, forming a
complex that translocates across the nuclear membrane [44–48]. In the
nucleus the Smad complexes in association with co-activators and
co-repressors and other transcription factors modulate the expression
of target genes as illustrated in Fig. 2. Fine tuning of TGF-β activity is
achieved through a balance of positive and negative effector molecules.
Of critical importance is the inhibitory Smad, Smad7, which inhibits
TGF-β signaling through binding to TβRl receptor, preventing recruit-
ment and phosphorylation of RSmads and also facilitating TβRl degra-
dation, leading to inhibition of RSmad activation [49].
3.2.1. Non-canonical TGF-ß signaling pathways
In addition to the Smadpathway, critical proﬁbrotic signaling cascades
independent of RSmads can be activated in a cell-speciﬁc and context-
dependent manner and mediate important TGF-β effects [50,51]. Of
great importancewith respect to theﬁbrotic effects of TGF-β is theﬁnding
that TGF-β stimulation leads to the activation of PI3K, which in turn
activates two important proﬁbrotic pathways: p21 activated kinase
(PAK2)-Abelson kinase (Abl) and Akt-mTOR1 pathways. Downstream
targets of c-Abl include known proﬁbrotic mediators such as PKCδ/
Fli-1, Egr, and Smad1 [52–55] as illustrated in Fig. 2. Activated c-Abl is
required for the activation of Smad1 and for the phosphorylation of pro-
tein kinase C-δ (PKC-δ), which in turn phosphorylates the transcription
factor Fli-1 reversing its inhibitory effect on collagen gene expression.
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Fig. 1. Cellular origins and pathways leading to activated myoﬁbroblasts. Insults caused by a variety of putative causative agents such as bacteria, toxins, ROS, or radiation in
genetically predisposed hosts result in inﬂammation. Activated inﬂammatory cells secrete cytokines and growth factors such as TGF-β which cause ﬁbroblast activation and differ-
entiation of endothelial and epithelial cells into myoﬁbroblasts. These cells produce excess amounts of ECM resulting in dysfunctional ﬁbrotic tissue.
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participates in the process of endothelial–mesenchymal transition [26].
The activation of Smad1 downstream of TGF-β is of particular interest
since total and phosphorylated Smad1 levels were signiﬁcantly elevated
in SSc skin biopsy samples and in cultured SSc ﬁbroblasts [54]. The
Akt-mTOR pathway plays an important role in various cell processes in-
cluding regulation of cell proliferation and metabolism as well as being
involved in some epithelial/mesenchymal transitions [56]. Another im-
portant non-Smad signaling pathway is through the activation of Jun
N-terminal kinase (JNK) resulting in the activation of c-Jun, a critical
proﬁbrotic transcription factor [50,51]. In addition to serine/threonine
phosphorylation, TβRI can also be phosphorylated on tyrosine residues
in response to TGF-β activation leading to activation of Erk1/2 MAPK,
which can play an important role by regulating myoﬁbroblast formation
as well as matrix synthesis [57–60]. Other studies have shown that tyro-
sine phosphorylation of TβRII, triggers activation of p38 MAPK signaling
[61,62].3.3. Connective tissue growth factor (CTGF/CCN2)
CTGF, also known as CCN2, is another pleotropic growth factor that
has recently emerged as an importantmediator of normal and patholog-
ical tissue ﬁbrotic responses [63,64] and it has been suggested to play a
crucial role in SSc tissue ﬁbrosis [65,66]. In vitro studies in cultured ﬁ-
broblasts have shown that the addition of recombinant CTGF or its
overexpression induced ﬁbrosis. Furthermore, in experimental mouse
models, elevated levels of CTGF were associated with the development
of ﬁbrosis, and suppression of CTGF reduced bleomycin-induced lung
ﬁbrosis [67]. TGF-β stimulates CTGF synthesis in ﬁbroblasts, vascular
smooth muscle cells and endothelial cells, and several studies have
shown that CTGF acts as a downstream mediator to enhance the
ﬁbrogenic action of TGF-β [68]. Indeed, the CTGF produced by these
cells in response to TGF-β stimulation in turn stimulates the synthesis
of such ECM components as type I collagen and ﬁbronectin in ﬁbroblastsand very likely also in endothelial cells [63,64]. Signiﬁcantly, Smad1 acti-
vation correlatedwith elevated CTGF protein and CTGF promoter activity
and DNA binding assays demonstrated that Smad1was a direct activator
of the CTGF gene [54]. Of considerable interest is theﬁnding that imatinib
mesylate, an inhibitor of c-Abl, blocked activation of the Smad1 pathway
in TGF-β stimulated normal ﬁbroblasts and abrogated stimulation of
CTGF expression in SSc ﬁbroblasts [54]. These observations indicate
that, at least in some circumstances, c-Abl is required for Smad-1 activa-
tion. It should also be noted that CTGF expression can be independently
stimulated through the RhoA/ROCK pathway [69] as illustrated in Fig. 2.
Currently, trials testing anti-CTGF antibodies in interstitial pulmonary ﬁ-
brosis (IPF) and liver ﬁbrosis are ongoing.3.4. Platelet derived growth factor
The platelet derived growth factor (PDGF) family consists of four dif-
ferent polypeptides, the original PDGF-A and PDGF-B, and the more re-
cently described PDGF-C and PDGF-D. The biologically active PDGFs
form disulﬁde-bonded dimers, such as PDGF-AA and PDGF-BB as well
as a PDGF-ABheterodimers. The PDGFs bind and activate two structurally
related tyrosine kinase receptors, PDGFRα and PDGFRβ. Ligand-induced
receptor homo- or heterodimerization leads to autophosphorylation of
speciﬁc tyrosine residues within the cytoplasmic domain. PDGF-A
activates PDGFRα, exclusively, whereas PDGF-B is capable of activat-
ing PDGFRα, PDGFRαβ and PDGFRβ. PDGF-AB can activate PDGFRα
and PDGFRαβ [70–72]. Receptor activation leads to overlapping sig-
nal transduction pathways including PI3K, Ras-MAPK, Src family kinases
and phospholipase Cγ (PLCγ) resulting in various cellular responses in-
cluding proliferation, chemotaxis and actin reorganization as illustrated
in Fig. 3. Multiple reports have implicated PDGF in ﬁbrotic reactions of
several organs, including pulmonary, renal and hepatic ﬁbrosis as
well as in SSc [73]. Fibroblasts are both major sources and targets
for PDGF-A since they express PDGFRα on their cell surface [74–76].
Thus, PDGF-A/PDGFRα signaling loops can stimulate ﬁbroblasts to
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Fig. 2. TGF-β signaling pathways critical for the ﬁbrotic response. Illustrated are canonical and non-canonical pathways originating from two representative dimeric receptors. Following
TGF-β binding, the TGFβRll receptor recruits a TGFβRl, either activin-like kinase-1 or activin-like kinase-5 and activates it by phosphorylaton. Activin-like kinase 5 (Alk 5) then speciﬁcally
phosphorylates receptor-regulated Smad2 and Smad3 which then complex with Co-Smad4 resulting in their transport to the nucleus where they interact with various co-activators or
co-repressors to regulate transcription of critical genes, here represented by connective tissue growth factor (CTGF) and α1(l) and α2 [1] collagen genes. Also illustrated are several
non-canonical pathways. An important one involves the phosphorylation and activation of the cellular Abelson non-receptor kinase (c-Abl) resulting in activation of several downstream
critical factors including Smad1, early growth response protein (EgR) and protein kinase C delta (PKC-δ), all of which contribute to the ﬁbrotic response.
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released by macrophages and hepatic stellate cells, with the latter
ones also pointing to a major role of PDGF-B/PDGFRβ-signaling in
liver ﬁbrosis [77,78]. Upon tissue injury PDGF signaling becomes acti-
vated to promote wound closure but PDGF signaling is tightly regulated
and turned off as soon as the physiologic repair processes are completed
[79]. Failure to terminate activated PDGF signaling may lead to exces-
sive scar formation and tissue ﬁbrosis.
3.5. Wnt-signaling
While β-catenin has a structural role linking transmembrane
cadherins to the actin cytoskleton, it also plays a critical role in canonical
Wnt signaling. In the absence of Wnt signals, β-catenin binds to and is
phosphorylated by a complex consisting of adenomatosis polyposis
coli (APC), axin, glycogen synthase kinase-3β (GSK-3β), and casein ki-
nase which promotes subsequent degradation of β-catenin. Wnt pro-
teins are secreted ligands that transmit their signal across the plasma
membrane by interacting with Frizzled receptors and low-density lipo-
protein receptor-related protein co-receptors (LRP5/6) as illustrated in
Fig. 3 [80]. Wnt receptor binding disrupts the complex resulting in the
stabilization of β-catenin which translocates to the nucleus, where it
binds to T-cell factor/lymphoid enhancer-binding factor (Tcf/Lef) toinduce target gene transcription such as axin-2 [81]. Aberrant activation
of the canonicalWnt signaling pathway has been implicated in a variety
of pathological processes including pulmonary, renal, dermal and liver
ﬁbrosis, aswell as, in scarring followingmyocardial infarction and ﬁbro-
sis accompanying muscular dystrophy [82–86]. Wnt signaling is tightly
controlled by an array of negative regulators, among which, Dickkopf
proteins (Dkk-1–4) have a key role. The best studied is Dkk-1, which
functions as a natural secreted antagonist of Wnt signaling [87,88].
3.6. Hedgehog signaling
Mammalian orthologs of the Drosophila melanogaster hedgehog
(Hh)morphogen are highly hydrophobic secretedpeptides and three dif-
ferent hedgehog proteins have been described, Sonic hedgehog (Shh),
Indian hedgehog, and Desert hedgehog with Shh being the most impor-
tant in the present context [89]. Patched (Ptc), a twelve-pass membrane
protein binds Hh ligands, but in the absence of ligand, Ptc interacts with
and inhibits Smoothened (Smo), a seven-pass membrane protein [90].
However, binding of Shh to Ptc1 induces conformational changes that
prevent Ptc1 from inhibiting Smo. The absence of Smo inhibition initiates
a series of intracellular events resulting in stabilization of Gli family zinc
ﬁnger transcription factors which in turn stimulate expression of Hh tar-
get genes [91] as illustrated in Fig. 3.While Hh signaling is critical during
Src
Profibrotic Gene 
Expression
TCF
Gli
PDGFR
Notch
P
P
c-Abl
-catenin
-Catenin
TISSUE FIBROSIS
P
P
NCID
-Secr
NCID
Wnt
Shh
Gli
Jag-1
PDGF
PPAR
MAPK
PI3K
PLC
Fig. 3. Growth factor/cytokine signaling pathways important in ﬁbrogenesis. Illustrated are the signaling pathways for platelet derived growth factor (PDGF), Notch, Wnt and Hedgehog.
Each of these pathways is activated by ligand-binding to speciﬁc receptors, but the subsequent signaling transmissionmechanisms between these pathways differ dramatically (see text).
For clarity of presentation they have been abbreviated with only the essential features presented.
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the pathogenesis of various diseases in adults, including a variety of ma-
lignancies [92–94]. A recent study has shown that overexpression of Shh
in cultured SSc ﬁbroblasts activates the Hh pathway, with accumulation
of the transcription factor Gli-2 and increased expression of Hh tar-
get genes [95]. Furthermore, Shh potently stimulated the production
of collagen and induced the differentiation of resting ﬁbroblasts into
myoﬁbroblasts. Overexpression of Shh in the skin of micewas sufﬁcient
to induce ﬁbrosis, and mice lacking one allele of the gene for the inhib-
itory receptor Ptc1 were more sensitive to experimentally-induced ﬁ-
brosis [95].
3.7. Notch signaling
Notch signaling, also ﬁrst discovered in Drosophila, is initiated by
binding ofmembers for two ligand families, Jagged andDelta-like. Bind-
ing of ligands such as Jagged-1 (Jag-1) results in cleavage of Notch re-
ceptors by the γ-secretase complex and release of the active Notch
intracellular domain (NICD) as illustrated in Fig. 3 [96,97]. Translocation
of theNCID into the nucleus activates the transcription of numerous tar-
get genes such as the Hairy/Enhancer of Split (Hes) [98]. AbnormalNotch signaling participates in the pathogenesis of several human dis-
eases including T-cell acute lymphoblastic leukemia and melanoma
[99,100]. Clinical trials with γ-secretase inhibitors already in progress
in patients with T-cell acute lymphoblastic leukemia have yielded
promising results [101]. There is accumulating evidence for the impor-
tance of Notch signaling in ﬁbrotic diseases, although the molecular
mechanisms involved in ﬁbroblast activation and stimulation of ECM
synthesis need clariﬁcation [102,103].
3.8. Endothelin-1
Endothelin-1 (ET-1) is a 21-amino acid polypeptide with potent
vasoconstrictor activity that plays a crucial role in the pathophysiology
of pulmonary arterial hypertension and has been identiﬁed as a prime
therapeutic target for this disorder [104,105]. A growing body of evi-
dence has implicated ET-1 as a participant in organ ﬁbrosis and numer-
ous studies have described a variety of its proﬁbrogenic activities. ET-1
has been shown to stimulate the synthesis of extracellular matrix mac-
romolecules such as collagen types I and III and to inhibit the production
of matrix degrading metalloproteinase-1 in cultured normal human
ﬁbroblasts [106,107]. Furthermore, increased production of ET-1 has
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experimentally induced pulmonary ﬁbrosis [109] providing strong
support to the concept that ET-1 also plays an important role in the
pathophysiology of SSc, pulmonary ﬁbrosis and other ﬁbrotic diseases
[110–112]. ET-1 also was found to be involved in the induction of EMT
[113]. The role of ET-1 in EMT appears to be mediated through the
endothelin A receptor (ET-A) via stimulation of endogenous TGF-β1 pro-
duction [114].
3.9. Strategies for inhibition of ﬁbrosis
3.9.1. Cellular phenotypic transitions resulting in myoﬁbroblast
formation
Recent delineation of the cellular phenotype transitions leading to
the activated myoﬁbroblast and the molecular identiﬁcation of the
pathways stimulating the ﬁbrogenic processes have suggested new
therapeutic approaches and targets. As discussed above and shown in
Fig. 1, there are four distinct potential cell sources of myoﬁbroblasts.
Three of thesemay be found as residents in the affected tissue including
ﬁbroblasts, endothelial cells and epithelial cells. Thus blocking their
transition into activated myoﬁbroblasts could prevent the initiation of
the ﬁbrotic process itself. The most direct transition is the conversion
of ﬁbroblasts into myoﬁbroblasts in which the activated cells express
α-SMA and synthesize markedly increased amounts of ECM compo-
nents. Undoubtedly, TGF-β is the most important causative agent in-
volved in the ﬁbroblast activation process as well as the mesenchymal
transformation of epithelial and endothelial cells. Thus, preventing
TGF-β action is clearly a potential therapeutic approach that may be
achieved at several levels.
3.9.2. Interfering with TGF-β expression and activation
The complex signaling pathways initiated by TGF-β receptor bind-
ing offer multiple points of potential therapeutic intervention. TGF-β
is constitutively synthesized and stored in an inactive form as a com-
plex with speciﬁc binding proteins. Thus, the expression of TGF-β and
the process of its release in an active form present therapeutic targets.
Pirfenidone has been studied in experimental models of pulmonary
ﬁbrosis in which it suppressed TGF-β gene expression at the tran-
scriptional level and signiﬁcantly reduced the tissue levels of TGF-β
mRNA and TGF-β in lavage ﬂuid [115]. Pirfenidone has been evaluated
in four randomized, double-blind, placebo-controlled clinical trials. The
collective results of these trials indicate that pirfenidone can reduce the
rate of decline in lung function asmeasured by changes in forced vital ca-
pacity or total lung capacity but had little effect on diffusing capacity or
resting arterial oxygen levels [116,117].
Several αv integrins can activate matrix-bound latent TGF-β and
antibodies to the integrin αvβ6 expressed on epithelial cells blocked
the activation of TGF-β preventing development of experimental lung
ﬁbrosis [118–120]. Such a speciﬁc antibody approach has the advantage
of conﬁning the blocking activity only to injury sites where αvβ6 is
expressed only in epithelia and not compromise other important func-
tions of TGF-β.
Angiotensin ll in certain circumstances exhibits remarkable proﬁbrotic
properties probably acting, at least in part, through stimulation of TGF-β
production [121,122]. Although angiotensin converting enzyme and
AT1R inhibitors can block experimental models of lung ﬁbrosis, there
are no published reports regarding the use of these drugs in humans
with pulmonary ﬁbrosis. Therefore, it is still unclear whether ATll inhibi-
tion would have beneﬁcial effects in ﬁbrotic conditions, although the
complex interactions betweenTGF-β andATll suggest that pharmacologic
inhibition of both systems may yield synergistic beneﬁcial effects.
Blocking or inactivating extracellular TGF-β is a possible approach
but results to date in humans have so far not been promising even
though a TGFβ1 inhibitor peptide attenuated the progression of lung ﬁ-
brosis in the bleomycin pulmonary ﬁbrosis model [123]. In a phase l/ll
double-blind, placebo controlled trial of CAT-192, a human anti-TGFβ1monoclonal antibody in patients with early diffuse SSc no improvement
was found in the extent or severity of skin involvement or in lung func-
tion parameters [124]. Also because of the wide-ranging functions of
TGF-β, interfering globally with this essential signaling molecule could
have untoward, toxic effects as was the case in the CAT-192 clinical
trial [124].
3.9.3. Inhibition of homing of circulating proﬁbrotic cells
Circulating ﬁbrocytes which express the CXCR4 receptor migrate
to ﬁbrotic sites in response to CXCL12 chemokine gradients and the
CXCL12/CXCR4 axis appears to be up-regulated in SSc [125]. CXCL12
antagonizing antibodies as well as AMD3100, a CXCR4 antagonist signif-
icantly reduced bleomycin-induced lung ﬁbrosis [126,127]. AMD3100 is
approved for the treatment of somemalignancies such as non-Hodgkin's
lymphoma, thus targeting the CXCL12/CXCR4 axis with available drugs
represents a potentially effective anti-ﬁbrotic therapeutic strategy.
Various experimental studies as well as ex vivo human data support a
pro-inﬂammatory and proﬁbrotic role for themonocyte chemoattractant
protein-1 (MCP-1/CCl-2). Inhibition of MCP-1 signaling by blocking its
receptor, CCR2, reduced the accumulation of ECM proteins in animal
models of skin and lung ﬁbrosis [128]. Since antagonists of CCR2 are cur-
rently in clinical trials for various diseases, theymay also be evaluated as
anti-ﬁbrotic agents.
3.10. Blocking TGF-β signaling pathways (see Fig. 2)
3.10.1. Inhibition of TGF-β receptor and canonical signaling
There have been several studies of speciﬁc inhibitors of TGF-β type l
receptor and the most thoroughly studied is SM305 which proved to
have excellent selectivity and potency against ALK5 and ALK4. In
normal dermal ﬁbroblasts, SM305 abrogated TGF-β-induced ECM
gene expression, ﬁbrogenic cytokine production, Smad3- and Smad2-
dependent transcriptional responses, and ﬁbroblast transdifferentiation
into myoﬁbroblasts [129]. These inhibitory effects of SM305 were asso-
ciated with potent selective suppression of TGF-β-induced phosphory-
lation and nuclear translocation of RSmads. However, in unstimulated
SSc ﬁbroblasts, SM305 only caused variable and modest reduction in
levels of type I collagen, and did not reverse constitutive Smad nuclear
accumulation or the proportion of α-SMA-positive myoﬁbroblasts.
Together, these results indicate that ALK5-Smad signal transduction
plays a fundamental role in mediating TGF-β-dependent proﬁbrotic
responses in normal ﬁbroblasts, whereas Smad nuclear accumula-
tion in SSc ﬁbroblasts appears to be ALK5 independent. In light of
its potent anti-ﬁbrotic activities in normal dermal ﬁbroblasts in vitro
and in vivo, SM305-mediated ALK5 inhibition represents a novel thera-
peutic strategy for controlling some TGF-β driven ﬁbrotic conditions.
The apparently contradictory results in SSc ﬁbroblasts emphasize the
complexity and heterogeneity of ﬁbrotic reactions and the requirement
to appropriately select therapeutic approaches to speciﬁc diseases.
3.10.2. Speciﬁc inhibition of Smad3
SIS3 is a potent and selective inhibitor of Smad3 that has been
shown to block the phosphorylation of Smad3 induced by TGF-βwith-
out affecting the phosphorylation of Smad2 [130]. SIS3 also inhibited
the interaction of Smad3with Smad4 aswell as the stimulation of colla-
gen production by TGF-β by normal ﬁbroblasts and their transition to
myoﬁbroblasts. Signiﬁcantly, SIS3 completely blocked the constitutive
phosphorylation of Smad3 as well as the increased type I collagen
expression in SSc ﬁbroblasts. The effects of SIS3 on EndoMT and on
experimentally-induced diabetic nephropathy were studied recently
[131]. EndoMT was induced in a mouse microvascular endothelial cell
line (MMEC) through the use of advanced glycation end products
(AGEs) and diabetic nephropathywas induced inmice by administration
of streptozotocin (STZ) [124]. SIS3 abrogated EndoMT in theMMEC, and
reduced renal ﬁbrosis and retarded progression of nephropathy in the
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be an effective anti-ﬁbrotic agent in selected diseases.3.10.3. Selective inhibition of TGF-β non-canonical signaling pathways
Avariety of targets present themselveswhenviewing themultiplicity
of components encompassing the non-canonical pathways initiated by
TGF-β. Most prominent among these is the non-receptor tyrosine kinase,
cAbl. The role of c-Abl in the ﬁbrogenic process was serendipitously
discovered when patients receiving treatment with imatinib mesylate
(Gleevec) for chronic myelogenous leukemia (CML) caused by Bcr-Abl
translocation had a remarkable reduction of bone marrow ﬁbrosis
[132]. Imatinibmesylate is a smallmolecule that speciﬁcally inhibits sev-
eral tyrosine kinases including c-Abl, PDGFR, c-kit and c-fms by blocking
the binding of ATP to the active kinase site. Imatinib mesylate has been
shown to be effective in preventing the development of organ ﬁbrosis
in the kidney, lung, liver, and skin in several animal models [133–138].
As seen in Figs. 2 and 3, inactivating c-Abl blocks several downstream ef-
fector molecules required for the full TGF-β response, while simulta-
neous inhibition of PDGF potentiates its anti-ﬁbrotic effect.
Imatinib has been used extensively and successfully in the treat-
ment of CML and gastrointestinal stromal tumors with relatively little
toxicity. However, the results in clinical trials of ﬁbrotic diseases have
been less clearcut. To date in ﬁve small clinical trials and several case
reports a total of 108 patients with severe SSc have been treated with
imatinib. Encouraging results were reported in 3 of 4 of these studies
whereas the ﬁfth study was prematurely terminated for safety reasons
[139]. In contrast, a recent trial of imatinib in patients with IPF failed to
accomplish the primary outcome measures with little beneﬁcial effect
on survival or lung function improvement, possibly owing to the short
term treatment period of only six months [140]. However, in phase ll
and lll clinical trials imatinib had a potent and prolonged beneﬁcial ef-
fect on pulmonary arterial hypertension and reversed vascular remod-
eling even when already established [141].3.10.4. Second generation and wide spectrum tyrosine kinase inhibitors
A signiﬁcant fraction of the patients treated in the imatinib anti-
ﬁbrotic trials withdrew because of mild to moderate side effects.
Dasatinib andnilotinib are second-generation tyrosine kinase inhibitors
with improved toxicity proﬁles that have proven effective in animal
models of SSc and both of them require only nanomolar concentrations
to obtain strong target inhibition compared to the micromolar concen-
trations required with imatinib [142]. In addition to c-Abl and PDGFR,
dasatinib inhibits sarcoma-tyrosine (src) kinases which regulate c-Abl
and are activated by TGF-β and PDGF. A speciﬁc inhibitor of src kinases,
SU6656, reduced skin ﬁbrosis in experimental models of SSc [143].
However, no clinical data is currently available for either of these drugs.
Nintedanib (BIBF 1120) is a potent intracellular inhibitor of tyro-
sine kinases that is in clinical development for the treatment of IPF
and various cancers [144]. Its targets include (PDGFR), vascular endo-
thelial growth factor receptors (VEGFR), and ﬁbroblast growth factor
receptors (FGFR). Because signaling pathways activated by these tyro-
sine kinase receptors have been shown to be involved in lung ﬁbrosis
[145] and other ﬁbrotic processes their inhibitionmay slowprogression
of IPF or liver ﬁbrosis [146–149]. In a rat model, such inhibition was
shown to prevent the development of bleomycin-induced lung ﬁbrosis
when nintedanib was administered before or during the ﬁbrotic phase
of the disease [147]. In a recently published clinical trial for IPF [150],
nintedanib at the highest dose employed produced a signiﬁcant im-
provement in the decline of forced vital capacity compared with the
placebo group. This dose also resulted in a lower incidence of acute
exacerbations as compared with placebo with relatively mild and toler-
able side effects. Given the intractable nature of IPF, these results suggest
that wide spectrum tyrosine kinases may prove useful in treatment of ﬁ-
brotic diseases.3.11. Rho-asssociated kinases
The intracellular mechanisms by which cytokines and growth fac-
tors such as TGF-β activate ﬁbroblasts and stimulate ECM production
are not completely understood. The small GTPase RhoA plays a cen-
tral role in cell motility and adhesion through reorganization of the
actin cytoskeleton. Activation of receptors switches RhoA from an inac-
tive, GDP-bound conformation to an active GTP-bound conformation,
which binds to and activates target molecules [151]. Cellular responses
to RhoA are mediated by downstream Rho-associated kinases (ROCK)
[152,153], which reorganize the actin cytoskeleton through phosphory-
lation of several substrates that contribute to the assembly of actin ﬁla-
ments and contractility, molecular events critical for the differentiation
of resting ﬁbroblasts into active myoﬁbroblasts. When cultured ﬁbro-
blasts were treated with TGF-β, inhibition of ROCK with the speciﬁc in-
hibitor Y27632 blocked the formation of myoﬁbroblasts and reduced
ECM production without cell toxicity [154]. The MAP kinase ERK, iden-
tiﬁed as a down-stream target of ROCK in SSc ﬁbroblasts, played a crit-
ical role in the proﬁbrotic response to TGF-β treatment. It is not certain
how ERKmediates its ﬁbrotic effects, but it may regulate Smad3 signal-
ing in certain cells or it may activate the transcription factor Sp1 which
can stimulate transcription of the type I collagen genes and which is el-
evated in ﬁbrotic conditions including SSc [155–158]. Interestingly, two
DNA intercalators, WP631 and mitoxantrone, have been shown to pre-
vent binding of Sp1 to the COL1A1 promoter in human dermal ﬁbro-
blasts. Both drugs inhibited basal COL1A1 production and mRNA
levels without cytotoxicity or apoptosis and prevented TGF-β stimula-
tion of expression [159]. These data suggest that Sp1-DNA intercalators
may be an effective approach for the treatment of ﬁbrotic diseases.
Inhibitors of hydroxymethylglutaryl-coenzyme A reductase such as
statins, which are widely used to lower serum cholesterol, have been
shown to have anti-ﬁbrotic effects [160–162], whichmight bemediated
by inhibition of ROCK. Statins interfere with the geranylgeranylation of
membrane RhoA [163,164], which prevents the activation of RhoA,
which in turn blocks the activation of ROCK. Furthermore, a speciﬁc in-
hibitor of geranylgeranyl transferase 1 inhibited type I collagen gene ex-
pression in normal and SSc ﬁbroblasts [165]. Thus, the anti-ﬁbrotic
activity of statins supports the anti-ﬁbrotic effects of ROCK inhibitors.
The ROCK inhibitor, fasudil, has been used in Japan and China for the
treatment of coronary and cerebral artery vasospasm [166,167]. Consid-
ering the very low rate of side effects and the favorable clinical experience
in those studies, ROCK inhibitors should be considered as promising can-
didates for targeted anti-ﬁbrotic therapy.
3.12. Caveolin-1
Caveolin-1, themost important structural component of caveolae, is
also found in several other cellular sites and is expressed in a variety of
cell types including epithelial cells, endothelial cells and ﬁbroblasts. Of
interest in the present context is its potential role in regulation of the ﬁ-
brotic reaction and prominent in this regard is its ability to bind and in-
hibit a substantial number of kinases [168]. High levels of caveolin-1 are
found in normal lung ﬁbroblasts, whereas much lower levels are found
in lung ﬁbroblasts from ﬁbrotic lungs of SSc and IPF patients [169–171].
This reduction in caveolin-1 is associatedwith increased activity of sev-
eral signaling kinases (MEK, ERK, JNK, and Akt) and increased expres-
sion of matrix molecules. An interesting ﬁnding is the localization in
caveolin-1 of the binding site which functions as a kinase inhibitor
(amino acids 82–101) known as caveolin-1 scaffolding domain (CSD).
When fused to the C terminus of the Antennapedia internalization se-
quence, CSD can enter cells with low caveolin-concentrations where,
like the intact molecule, it can bind kinases, inhibit their activity and
also inhibit collagen expression [171]. In caveolin-1 null mice, alveolar
walls are thickened, the diameter of alveolar spaces is reduced, and
ECM is signiﬁcantly increased [172–174]. In the bleomycin lung ﬁbrosis
model caveolin-1 levels are depressed, and systemic administration of
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between low caveolin-1 levels and lung ﬁbrosis.
TGF-β and caveolin-1 signaling interact in several ways. TGF-β
inhibits caveolin-1 expression in several types of cells including lung
and dermal ﬁbroblasts, while caveolin-1 modiﬁes TGF-β signaling by
inhibiting Smad3 phosphorylation and its translocation to the nucleus
[175]. Caveolin-1 also regulates TGF-β signaling through its effects on
the endocytosis of TGF-β ligand-receptor complexes, which are present
in both caveolin-1 rich lipid rafts and clathrin-rich early endosomes
[176,177]. Early endosomal internalization increases TGF-β signaling
while caveolin-1-rich lipid raft internalization leads to receptor degrada-
tion and inhibition of TGF-β signaling [176]. Thus, the loss of caveolin-1
in ﬁbrotic tissues will promote TGF-β signaling by early endosomal
internalization.
The above discussion must be viewed with some caution, however,
since other reports have found higher levels of caveolin-1 in some
SSc dermal ﬁbroblasts than in normal dermal ﬁbroblasts and
found that caveolin-1 overproduction enhanced collagen expression
while caveolin-1 depletion inhibited collagen expression [178,179].
Furthermore, caveolin-1 was found to be a positive regulator of
phospho-Smad1 and CTGF, a powerful proﬁbrotic cytokine [178].
In spite of these caveats, the use of CSD as a molecular therapeutic
must be considered for treating certain ﬁbrotic conditions, such as in
the lung, because caveolin-1 regulates several signaling pathways
which may be a more effective approach than use of agents targeting
a single speciﬁc pathway.
3.13. Transcription and other intracellular factor modulation
3.13.1. The c-Abl/PKCδ/Fli-1 pathway
As discussed above, c-Abl has a critical role in mediating the ﬁbrotic
response initiated by TGF-β. An important part of this activity is the
phosphorylation/activation and nuclear localization of PKCδ. PKCδ
then phosphorylates the transcriptional repressor Fli1 at threonine
312 which promotes its interaction with p300/CREB-binding protein-
associated factor and subsequent acetylation. These molecular events
cause Fli-1 dissociation from the human α2(I) collagen gene promoter,
resulting in enhanced transcription of the gene (see Fig. 2) [180]. A
breakthrough study on the role of PKCδ in the regulation of collagen
gene expression found that selective inhibition of PKCδ markedly de-
creased the production of collagen by SSc ﬁbroblasts [181,182] and a
very speciﬁc peptide inhibitor of PKCδ is now being investigated as a
protective agent for reperfusion injury after myocardial infarction
[183]. Previous extensive animal experiments have shown this peptide
to be a highly effective and speciﬁc inhibitor of PKCδwithminimal toxic
effects, suggesting its potential utility in ﬁbrotic disorders.
3.13.2. The AP-1 transcription factor family
The transcription factor AP-1 is a heterodimeric molecule composed
of members of the Jun (c-jun, junB and junD) and the Fos family (cFos,
FosB, Fra-1 and Fra-2). Currently, the most important of these with re-
spect to ﬁbrotic conditions are c-Jun, JunD, cFos, and Fra-2. TGF-β stimu-
lated the expression of Fra-2 in dermal ﬁbroblasts through ERK signaling
and JunD through Smad3 pathway [184]. JunD, cJun and cFoswere found
to be overexpressed in the skin and dermal ﬁbroblasts of SSc patients
[185]. Interestingly, the effects of AP-1 on collagen synthesis seem
not to be restricted to SSc dermal ﬁbroblasts but might also occur
in cardiac, renal, and keloid ﬁbroblasts [186–188]. These are impor-
tant ﬁndings since they suggest that a critical mode of TGF-β
proﬁbrotic activity is through up-regulation of AP-1 and its resul-
tant transcriptional activity. In this regard it should be noted that
AP-1 up-regulates tissue inhibitor of metalloproteinases (TIMP)
while decreasing matrix metalloproteinase-1 (MMP-1) [189]. Thus,
AP-1 not only increases the production of matrix components, but
also inhibits their degradation resulting in their net accumulation.T-5224 is a small molecule inhibitor of AP-1 that was developed
based on the x-ray crystal structure of the basic region leucine zipper
domain of the AP-1–speciﬁc DNA complex composed of c-Jun/c-Fos.
In a preclinical animal study, T-5224 had an excellent safety proﬁle
[190]. T-5224 blocked the in vitro effects of TGF-β on the differentia-
tion of resting ﬁbroblasts into myoﬁbroblasts and stimulation of ECM
production and in vivo prevented dermal ﬁbrosis induced by bleomycin
[185]. Because of the potent anti-ﬁbrotic effects and the favorable safety
proﬁle of T-5224, inhibition of AP-1 signaling by T-5224 and other sim-
ilar potential agents must assume a high priority for the treatment of ﬁ-
brotic diseases in well-controlled clinical test settings.
In contrast to the pathways used in the up-regulation of expres-
sion of c-Jun by TGF-β and PDGF, activation of c-Jun by phosphoryla-
tion proceeds through the activity of c-Jun N-terminal kinase (JNK).
The selective JNK inhibitor, CC-930, prevented the phosphorylation
of cJun, reduced the stimulatory effects of TGF-β and PDGF on colla-
gen production, prevented collagen accumulation and dermal thick-
ening in bleomycin and Tsk-1 mice experimental ﬁbrotic models,
and, remarkably, it induced regression of established experimental
ﬁbrosis [191]. Phase III clinical trials with various inhibitors of JNK
for the treatment of rheumatoid arthritis and different types of cancer
showed that inhibition of JNK is well tolerated in humans [192]. Mice
treated with CC-930 did not show any signs of toxicity and initial re-
sults from dosing studies in healthy human volunteers have indicated
that CC-930 is well tolerated [193]. Thus, JNK is a viable target for
treatment of ﬁbrotic diseases.
3.13.3. JAK2 and Stat3
Janus kinases (JAKs) are receptor-associated tyrosine kinases with
central roles in cytokine- and growth factor signaling. Upon cytokine
binding to the receptor, JAK kinases become activated and phosphory-
late tyrosine residues in the cytoplasmic region of the receptor [194].
STATs (Signal Transducer and Activator of Transcription) are latent cy-
toplasmic transcription factors that are recruited to these phosphorylat-
ed receptor sites and become activated by phosphorylation by JAKs of a
conserved tyrosine residue near the C-terminus after recruitment to an
activated receptor complex. Activated STATs then dimerize and translo-
cate into the nucleus where they activate transcription of several target
genes [194]. JAK2 is a key-regulator of cytokine signaling and alterations
of JAK2 signaling cause profound changes in response to cytokine stim-
ulation. Point mutations in the JAK2 gene, which result in constitutive
activation of JAK2, are critical in the pathogenesis of myeloproliferative
diseases [194,195] and this critical role has stimulated the development
of JAK2 inhibitors, several of which are currently being evaluated in
clinical trials with promising results [196].
Increased activation of JAK2 and STAT3 were detected in the skin of
SSc patients, which persisted in cultured SSc ﬁbroblasts [197]. The selec-
tive JAK2 inhibitor, TG 101209, reduced basal collagen synthesis in SSc ﬁ-
broblasts and prevented the stimulatory effects of TGFβ on ﬁbroblasts.
Treatmentwith TG101209not only prevented bleomycin-inducedﬁbro-
sis, but also effectively reduced skin ﬁbrosis in the Tsk-1 mice animal
model of tissue ﬁbrosis [197]. JAK2 may not only act as a downstream
mediator of TGF-β but may also amplify TGF-β signaling by stimulating
the expression of TGF-β since incubation with TG 101209 caused a
dose-dependent decrease in themRNA levels of TGF-β in SSc ﬁbroblasts.
Furthermore, other studies demonstrated that inhibition of STAT3 and
overexpression of suppressor of cytokine signaling 1 (SOCS1) reduced
the expression of TGF-β [198,199]. Considering that several pharmaco-
logical inhibitors of JAK2 are available and appear to be well tolerated,
targeting JAK2 for the treatment of ﬁbrotic diseases deserves careful
consideration.
3.13.4. Peroxisome proliferator-activated receptor gamma (PPARγ)
PPARγ is a nuclear receptor originally identiﬁed in adipose tissue
but is broadly expressed and plays a crucial role in glucose and lipid
metabolism. Recent studies have described new functions for PPARγ
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PPARγ expression accompanied progression of ﬁbrosis in experimental
models of lung, liver and kidney ﬁbrosis and was a consistent ﬁnding
in skin and lung tissues from SSc patients [200]. In addition, adiponectin
levels, a sensitive and speciﬁc index of PPARγ activity, were reduced in
the serumof patientswith diffuse cutaneous SSc and correlated inversely
with the extent and severity of skin sclerosis [201]. Thus, adiponectin
might have potential as a biomarker in SSc. Several proﬁbrotic factors
such as TGF-β, Wnt proteins and IL-13 suppress PPARγ activity or ex-
pression [202]. Treatment of normal ﬁbroblasts with the endogenous
PPARγ prostanoid ligand, 15d-prostaglandin J2, or with the PPARγ
pharmacologic agonist, rosiglitazone, abrogated TGF-β induced ﬁ-
brotic responses [203–205]. In addition, PPARγ blocks EMT and the
differentiation of preadipocytes into ﬁbroblasts [206], a putative
novel mechanism of tissue ﬁbrosis. Since rosiglitazone is already
used in the treatment of diabetes mellitus, evaluation of it as an
anti-ﬁbrotic agent in clinical trials appears warranted.
3.14. Inhibition of other proﬁbrotic signaling pathways
3.14.1. Wnt signaling
TGF-β appears to be the major factor activating the canonical Wnt
pathway in ﬁbrotic diseases probably mediated largely by a decrease
of Dkk-1 and although other molecular mechanisms are possible, the
addition of recombinant Dkk-1 blocked the stimulatory effects of TGF-β
on the canonicalWnt pathway in ﬁbroblasts [207].Wnt signaling caused
the transition of resting ﬁbroblasts into activatedmyoﬁbroblasts, and in-
creased the production of ECM components. Dkk-1 is currently being in-
vestigated as a potential therapeutic target in other diseases and the
cumulative data suggest that inhibition of the canonical Wnt pathway
might be an effective approach to target TGF-β signaling in ﬁbrotic
diseases
3.14.2. Hedgehog signaling
Abnormal stimulation of Hh signaling might be driven by several
factors. Hypoxia at levels similar to those observed in skin of SSc pa-
tients induces the expression of Shh [208,209]. However, a more likely
general scenario is that proﬁbrotic cytokines including TGF-β, PDGF,
and Wnt drive Shh overexpression [210–212]. It has been shown that
Shh stimulated resting ﬁbroblasts to differentiate into myoﬁbroblasts
and that overexpression of Shh inmice caused accumulation of collagen
and dermal thickening [213]. Thus, Hh signaling might play a central
role in the pathogenesis of ﬁbrosis. Both Smo-speciﬁc siRNA or the
small-molecule inhibitor LDE223, a highly selective antagonist of the
Hh coreceptor Smo effectively blocked the aberrant activation of the
hedgehog pathway while LDE223 prevented bleomycin-induced der-
mal ﬁbrosis [214]. In addition, treatment of Tsk-1 mice with LDE223
prevented progression of ﬁbrosis and induced its regression [214]. Sev-
eral small molecule inhibitors of Smo including LDE223 are currently
being evaluated in clinical anti-cancer trials with minimal side effects
reported so far. Thus, pharmacologic inhibition of the Hh pathway
might be a promising approach to treatment of ﬁbrotic disorders as il-
lustrated in Fig. 3.
3.14.3. Notch signaling
Recent studies in SSc skin suggest that inﬁltrating T cells expressing
the Jag-1 ligand might activate Notch signaling in ﬁbroblasts leading to
their transition to myoﬁbroblasts with increased expression of ECM
[102,103]. Although Notch signaling may be induced under hypoxic
conditions or by TGF-β, the detailedmolecularmechanisms responsible
for this transition remain to be determined [215–217]. Such activation
of Notch signalinghas also been found inmousemodels of dermalﬁbro-
sis [218]. Treatment with the γ-secretase inhibitor DAPT, which blocks
Notch signaling, signiﬁcantly decreased experimental pulmonary and
dermal ﬁbrosis in mice and in SSc dermal ﬁbroblasts [102,219]. Since
various inhibitors of γ-secretase are in clinical trials for different typesof malignancies, similar trials in ﬁbrotic diseases appear both feasible
and warranted.
3.15. Other important pathogenetic mechanisms in ﬁbrotic diseases
3.15.1. Role of micro RNAs in ﬁbrosis
MicroRNAs (miRNAs) are small (~22 nucleotides), evolutionarily
conserved non-coding RNA which modulate the expression of protein
coding genes at the post-transcriptional level by binding complementa-
rily to the 3′ untranslated region (UTR) of target mRNAs and suppress
expression by either inhibiting mRNA translation or facilitating mRNA
degradation [220]. Approximately 1400 miRNAs have been identiﬁed
to date in humans with most miRNA genes being located in introns,
exons and UTRs of protein coding genes [221]. Although the role of
miRNA in cancer has been extensively studied, recent interest has been
devoted to elucidating their participation in tissue ﬁbrosis and ﬁbrotic
diseases [222]. Several miRNA, including let-7, miR-21, mir-29 and
miR-155 are regulated by TGF-β and their targets are mRNAs coded by
genes involved in matrix homeostasis such as those encoding collagens,
matrix metalloproteinases, and Smad signaling proteins. miR-29 and
let-7 are anti-ﬁbrotic [223] whereas miR-21 andmiR-155 are proﬁbrotic
and their expression is increased in ﬁbrotic reactions [224]. Conversely,
miR-29 was found to be markedly down-regulated in SSc dermal ﬁbro-
blasts and skin [225]. Overexpression of miR-29 in SSc ﬁbroblasts de-
creased the levels of type 1 and type lll collagens demonstrating a
direct effect of miR-29. Similar reduction of miR-29 was observed in
ﬁbrotic reactions in other organs, including heart, kidney and lung.
TGF-β, PDGF-B or IL-4 reduced the levels of miR-29 in normal ﬁbroblasts
to levels similar to those observed in SSc ﬁbroblasts and amarked re-
duction was also seen in the bleomycin model of skin ﬁbrosis [225].
Although hypothetically regulation of miRNA expression could be
therapeutically exploited, presently there are considerable practical
barriers to its implementation.
3.15.2. The immune response and ﬁbrotic reactions
In many instances, a persistent inﬂammatory reaction character-
ized by accumulation of immune cells including various lymphocyte
populations and macrophages and the release of growth factors and
cytokines by these cells lead to activation of myoﬁbroblasts and a ﬁ-
brotic response. Owing to space limitations and to the availability of
several outstanding recent reviews covering the immunologic and in-
ﬂammatory aspects of tissue ﬁbrosis [226,227], the present discussion
will be conﬁned to a brief review of the direct involvement of the im-
mune response in promoting or inhibiting ﬁbrogenesis. Of singular im-
portance in this regard is the role of Toll-like receptors (TLRs) which
are activated not only by microbial ligands termed pathogen-associated
molecular patterns (PAMPs) which are speciﬁcally recognized by TLRs,
but also a variety of ligands derived from host components collectively
referred to as damage-associated molecular patterns (DAMPs) as well
as nucleic acid-containing immune complexes [228]. TLRs are found
not only in cells of the immune system but also in ﬁbroblasts. Type I in-
terferon production, linked to innate immune signaling through TLRs,
can result in TLR3-mediated responses in normal skin ﬁbroblasts [229].
While TLR3 is an endosomal receptor, TLR4 is expressed on the ﬁbroblast
cell surface and can recognize various DAMPs. Although activation of
TLR4 induces amodest ﬁbrotic reaction by itself, it stimulates a synergis-
tic response in association with TGF-β [230]. Thus, ﬁbroblast innate im-
mune signaling might be a critical contributor to the perpetuation of a
proﬁbrotic response.
The adaptive immune response is complex in that it contributes
both proﬁbrotic and anti-ﬁbrotic aspects. The TH2 proﬁbrotic responses,
are characterized most importantly by the production of IL-13, which
has been shown to be a potent stimulator of ﬁbroblast proliferation
and collagen production and when overexpressed induced skin and
lung ﬁbrosis in various experimental models [231]. Elevated levels of
IL-13 have been found in patients with SSc and it has been implicated
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brosis [232–234]. A recent study demonstrated that IL-13 signaling via
IL-13Ra [2] activated AP1 which then stimulated the transcriptional ac-
tivity of the TGF-β promoter. In contrast, the inhibition of IL-13 signal-
ing reduced the production of TGF-β and markedly reduced collagen
deposition in bleomycin-induced pulmonary ﬁbrosis [235]. There are
two phase II, double-blind placebo, randomized-controlled trials cur-
rently ongoing in SSc-ILD and IPF in which a fully humanized monoclo-
nal antibody against human IL-13 is being tested.
TH1 effector T cells, as well as natural killer and natural killer T
cells, produce IFN-γwhich inhibits ﬁbrosis, at least in part, by antagoniz-
ing the activity of TGF-β. IFN-γ inhibits the phosphorylation of Smad3 as
well as inducing the expression of inhibitory Smad7 [236–238]. IFN-γ
also blocks the TH2 cytokine-induced differentiation of peripheral blood
monocytes into ﬁbrocytes [239]. In spite of this supporting evidence, clin-
ical studies testing the therapeutic potential of IFN-γ in IPF, SSc and other
ﬁbrotic disorders have been mostly disappointing [240].
IL-17A, expressed by TH17 cells, has been implicated in the path-
ogenesis of pulmonary, cardiac and hepatic ﬁbrosis [241–243]. The
proinﬂammatory cytokines IL-1β and IL-23 have been identiﬁed as
initiators of TH17 responses and it has been found that in some circum-
stances TGF-βmay partially exert its ﬁbrotic effects through IL-17A pro-
duction [241,244]. Extracellular bacteria and certain fungi can lead to
inﬂammasome activation and IL-6 production, which in the presence
of TGF-β1, can drive TH17 differentiation [226]. Il-6 has been reported
to be up-regulated in the serum, dermal ﬁbroblasts and peripheral
blood mononuclear cells of SSc patients, and found to correlate with
the extent of skin ﬁbrosis [245]. Blocking of IL-6 in vitro decreased col-
lagen production, and IL-6 deﬁciency attenuated lung ﬁbrosis in the
bleomycin model [246]. Tocilizumab, a humanized monoclonal anti-
body directed against the IL-6 receptor, has been approved for the treat-
ment of RA. Although preliminary data in a small number of patients
from one study on the effects of tocilizumab on polyarthritis in SSc pa-
tients did not show any change in the extent of cutaneous involvement
over a 6-month period [247], there is a currently ongoing trial to exam-
ine the effects of tocilizumab in diffuse SSc.
3.16. Role of reactive oxygen species (ROS) in ﬁbrotic diseases
Numerous studies have provided compelling evidence for the in-
volvement of ROS in the development of tissue ﬁbrosis [248–250]. Al-
though ROS are produced under physiological conditions and are
essential for many intracellular reactions including ﬁbroblast prolifera-
tion, there is evidence that SSc ﬁbroblasts produce ROS constitutively
and that elevated ROS levels may be involved in the increased collagen
expression in these cells [251]. In addition increased urinary 8-oxodG
levels in SSc patients suggest marked oxidative stress [252]. Although
several classes of enzymes can produce ROS, in the present context the
most important is the NADPH oxidase (NOX) family of oxidoreductases,
especially NOX4 which is the most widely distributed isoform. NOX4 is
one of seven NADPH isoforms and like the others its structure consists
mainly of a six-transmembrane domain known as the gp91phox domain
[253,254]. Despite their extensive similarity in structure and enzymatic
function,members of theNOX family differ in theirmechanismof activa-
tion. In particular, NOX4 requires interaction with a second membrane-
bound subunit, p22 phox, and in contrast with other members of the
NOX family does not require other subunits [255]. NOX4 generates pre-
dominantly hydrogen peroxide (H2O2) rather than superoxide (O2-)
[256,257], although it is able to generate superoxide under speciﬁc
conditions.
Because of the increasing interest in the potential role of ROS in
ﬁbrogenic processes in a variety of tissues and the realization that
NOX family members are key effectors, substantial efforts are now
being devoted to develop selective NOX inhibitors. The ﬁrst of these
to be obtained are the triazolo pyrimidines such as VAS2870 and
VAS3947, which inhibit NOX speciﬁcally but are not isotype selective[258]. These compounds have been shown to be effective in vitro in
several cell systems expressing different NOX isotypes. However, be-
cause of the lack of isotype speciﬁcity, intense efforts have been de-
voted to the development of NOX4-speciﬁc or selective inhibitors
[259]. To date the best of these are pyrazolopyridine dione derivatives,
the most potent of which is GKT136901. This and similar compounds
demonstrated good oral bioavailability and safety proﬁles as well as
dual inhibitory activity for NOX4 and NOX1 in the nanomolar range
and have been shown to inhibit EMT and prevent bleomycin-induced
pulmonaryﬁbrosis. Theseﬁndings suggest that the best pyrazolopyridine
dione derivatives warrant clinical trials for treatment of IPF and other ﬁ-
brotic disorders.3.16.1. Matrix stiffness and ﬁbrogenesis
Recent studies have convincingly demonstrated that the mechan-
ical properties of the ECM can modulate the behavior of resident cells
including regulation of their proliferation, biosynthetic activities and
stage of differentiation, although the molecular mechanisms mediat-
ing these activities are only beginning to be understood. When lung
ﬁbroblasts were cultured on polyacrylamide substrates of varying stiff-
ness, they responded by producing increasing amounts of polymerized
α-SMA [260,261]. This actin polymerization resulted in nuclear translo-
cation ofMKL1, a cofactor that plays a central role in expression of ﬁbrot-
ic genes including α-SMA. Furthermore matrix stiffening promoted
production and activation of RhoA, increased ROCK activity and en-
hanced ﬁbroblast contractility. Inhibition of RhoA/ROCK blocked these
responses including MKL1 nuclear translocation and myoﬁbroblast dif-
ferentiation. Similar results were obtained with hepatic stellate cells
which became progressively myoﬁbroblastic with increasing substrate
stiffness [262].
These experiments suggest that as ﬁbrogenesis proceeds and tissues
become increasingly stiff, a vicious cycle can be initiated in which the
stiffness itself can promote further ECM production. Furthermore, these
ﬁndings suggest that therapeutic approaches aimed at the reduction of
tissue stiffness may prove to be extremely potent anti-ﬁbrotic agents.
As discussed above, RhoA/ROCK inhibitors including statins are already
available and may be more generally useful as anti-ﬁbrotic drugs than
currently understood. A substantial portion of ECMstiffness can be attrib-
uted to the crosslinking of collagenmediated by the copper-requiring en-
zyme lysyl oxidase, rendering controlled inhibition of lysyl oxidase a
potential therapeutic approach. In this regard it should also be pointed
out that the drug d-penicillamine, which was extensively utilized as an
anti-ﬁbrotic agent in the past [263–266] but was discredited following
a high dose versus low dose comparative study [267], is a potent inhib-
itor of collagen crosslinking and may, therefore, be extremely effective
in reducing tissue stiffness. These considerations should lead to the
re-evaluation of d-penicillamine as an anti-ﬁbrotic agent. Another po-
tential approach to the ﬁbrotic stiffness problem in carefully selected
cases is the direct injection of clostridial collagenase into the affected
tissue. This technique has been used successfully in nonsurgical treat-
ment of Dupuytren's contracture [268].3.16.2. Inhibition of ﬁbrosis by an endostatin-1 derived peptide
A recent novel and potentially ground-breaking study has shown
that a cell-permeable peptide corresponding to the carboxy terminal
end of the endostatin-1 molecule is capable of exerting remarkable ef-
fects on the pattern of gene expression of human normal ﬁbroblasts in
culture [269]. The peptide caused a potent anti-ﬁbrotic effect modulat-
ing several aspects of ﬁbroblast biology including a decrease in expres-
sion of the important proﬁbrotic transcription factor EGR-1, reduction
of the expression of type I collagen and ﬁbronectin, and inhibition of
the expression of lysyl oxidase, the main collagen crosslinking enzyme.
This study opens up the possibility of utilizing cell-permeable peptides
for the treatment of SSc, IPF, and other ﬁbrotic diseases.
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The present challenges facing the ﬁeld of ﬁbrotic diseases in terms of
therapy bear some similarities to the approach for cancer treatment. The
treating physicians are confrontedwith complex pathogenetic processes
which, although similar in theirﬁnal outcome, are quite diverse in specif-
ic molecular mechanisms. Thus, identifying critical targets and appropri-
ate, effective therapies is extremely difﬁcult. Owing to the diversity and
heterogeneity of the ﬁbrotic diseases with respect to their etiology and
pathogenesis, novel screening approaches will be required to character-
ize and identify particular pathways operative in individual cases. Sub-
stantial progress in this direction has been made in the cancer ﬁeld,
mainly due to the availability of large data bases documenting genetic al-
terations in malignant cells. While this approach has at best a limited
place in ﬁbrotic disease, RNA microarray screening of samples derived
from affected tissues is feasible and is currently being implemented.
Such analyses have been carried out comparing samples from ﬁbrotic tis-
sue fromSSc and IPF patients and control tissues inwhich substantial dif-
ferences were observed between the normal and ﬁbrotic samples.
However, based upon this kind of data it has not been possible, as yet,
to develop pathogeneticmodels which could lead to rational therapeutic
approaches. As detailed in the text, there has been an explosive growth
in new ﬁndings documenting alterations in potentially proﬁbroticTable 1
Anti-ﬁbrotic therapeutic targets and pharmacologic agents.
Target Agent
TGF-β expression and activation Pirfenidone
αvβ6 antibody
ATI and ATII receptor blockers
ACE inhibitors
CAT-192 (anti-TGF-β1 monoclonal AB)
Caveolin scaffolding domain (CSD)
TGF-β Signaling pathways
Canonical
TBR1 SM305
SMAD3 SIS3
Non-canonical
c-Abl Imatinib mesylate
PDGFR Dasatinib
c-kit Nilotinib
PKC-δ Small speciﬁc polypeptide
Rottlerin derivatives
CTGF Monoclonal CTGF antibodies
Inhibition of ﬁbrocyte homing
CXCL12 Antibody
CXCR4 AMD3100 and others
CCR2 inhibitors (PF-04136309)
Src dasatinib, SU6656
VEGFR Nintedanib (BIBF1120)
FGFR Sorafenib
Other intracellular pathways
JAK2 TG 101209
Wnt Dkk-1
Hedgehog LDE223
Notch DAPT
RhoA Statins, GGT inhibitor
ROCK Y27632, fasudil
MEK, ERK,JNK, Akt, caveolin scaffolding domain (CSD)
JNK CC-930
Transcription factors
AP-1 T-5524
Fli-1 Macrolide antibiotics
Sp1 Intercalating agents
PPARγ Rosiglitazone
Other mechanisms
IL-13 Humanized monoclonal AB
IL-6 receptor Tocilizumab
TLR TLR inhibitors (E5564, TAK-242)
Nox4 (ROS) GKT136901
ET-1 Bosentan, other ET receptor blockers
Matrix stiffness, collagen crosslinking D-penicillamine, clostridial collagenasegrowth factors/cytokines and in their signaling pathways. The chal-
lenge is how to apply these ﬁndings in individual cases. Presently,
the only way to determine such changes is by invasive biopsies and
even then sophisticated screening andmolecular analyses of the samples
would be difﬁcult at best or marginally informative. Thus, there is an ur-
gent need for the identiﬁcation of novel biomarkers, most desirably from
serum or plasma samples, which have the power to categorize ﬁbrotic
reactions with respect to the active pathogenetic mechanisms and
pathways.
A second major difﬁculty is the lack of suitable surrogate parameters
capable of measuring the effectiveness of novel therapeutic agents. As
listed in Table 1 (and this list is by nomeans complete) there is a plethora
of drugs which are attractive candidates based largely on in vitro evi-
dence from laboratory studies and supportive animal experimental ﬁnd-
ings, although they have not been appropriately tested in controlled
clinical studies. Constructing well designed controlled clinical trials will
be a difﬁcult although a quite necessary step that will require the coop-
eration of multiple investigators and centers using both non-invasive
and invasive measurements as discussed recently for SSc clinical trials
[270]. On the positive side, many existing drugs have been approved
for other purposes (e.g. imatinib, rosiglitozone) eliminating the necessity
for extensive safety testing. Another feature that is nowbecoming appar-
ent and that ﬁbrotic diseases share with cancer is the necessity of using
multiple drugs to affect different pathways. This is due to the fact that
the pathogenetic mechanisms of ﬁbrotic diseases consist of complex
networks of multiple and often redundant pathways and blocking a sin-
gle node, while occasionally effective, will usually not be sufﬁcient or
effective.
However, it is expected that in the near future translational medicine
will be able to successfully overcome these serious challenges and con-
vert the extensive knowledge acquired recently about the cellular and
molecular mechanisms of tissue ﬁbrosis into effective therapeutic ap-
proaches for the devastating and currently incurable ﬁbrotic diseases.
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